247022-37-3

Basic information

• Product Name: 4-Piperidinecarboxylic acid, 1-phenyl-, ethyl ester
• Synonyms: 4-Piperidinecarboxylic acid, 1-phenyl-, ethyl ester;ethyl1-phenylpiperidine-4-carboxylate
• CAS NO: 247022-37-3
• Molecular Formula: C₁₄H₁₉NO₂
• Molecular Weight: 233.30616
• Mol File: 247022-37-3.mol

Chemical Properties

• Boiling Point: 337.1±35.0 °C(Predicted)
• Appearance: /
• Density: 1.081±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.65±0.20(Predicted)
• CAS DataBase Reference: 4-Piperidinecarboxylic acid, 1-phenyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinecarboxylic acid, 1-phenyl-, ethyl ester(247022-37-3)
• EPA Substance Registry System: 4-Piperidinecarboxylic acid, 1-phenyl-, ethyl ester(247022-37-3)

Safety Data

• Hazardous Substances Data: 247022-37-3(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
4-Piperidinecarboxylic acid, 1-phenyl-, ethyl ester is used as a research compound for the synthesis and study of various chemical structures and reactions. Its unique properties make it a valuable tool in understanding the behavior of piperidine-based compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-Piperidinecarboxylic acid, 1-phenyl-, ethyl ester is used as an intermediate in the development of new drugs. Its structural characteristics allow for the exploration of potential therapeutic applications and the creation of novel pharmaceutical agents.
Used in Drug Synthesis:
4-Piperidinecarboxylic acid, 1-phenyl-, ethyl ester is used as a key component in the synthesis of certain drugs, particularly those with piperidine-based structures. Its presence in the synthesis process can contribute to the development of new medications with improved efficacy and safety profiles.
Used in Quality Control and Analysis:
In the context of quality control and analytical chemistry, 4-Piperidinecarboxylic acid, 1-phenyl-, ethyl ester can be used as a reference material or standard for the identification and quantification of related compounds in various samples. This helps ensure the accuracy and reliability of analytical results in research and industry settings.

Upstream product

• 1126-09-6 4-carbethoxypiperidine 
• 603-33-8 triphenylbismuthane 
• 1465827-63-7 1-benzoyloxypiperidine-4-carboxylic acid ethyl ester 
• 780-69-8 triethoxyphenylsilane 
• 591-50-4 iodobenzene 

Downstream Products

• 111153-74-3 4-formyl-1-phenylpiperidine 
• 94201-40-8 1-phenylpiperidine-4-carboxylic acid 
• 697306-45-9 (1-phenylpiperidin-4-yl)methanol 
• 660406-85-9 1-(1-phenylpiperidin-4-yl)-2-cyanoethan-1-one 

Relevant articles and documents

Copper(II) pivalate/oxone: An improved promoter system for aryl transfer via organo-bismuth reagents

As part of a medicinal chemistry project, it was necessary to develop effective conditions for the arylation of hydroxyl groups prone to elimination. Modest success was achieved using triarylbismuth reagents under literature conditions. Based on the side

Copper-Catalyzed Electrophilic Amination of Alkoxyarylsilanes

We report a copper-catalyzed amination reaction between simple alkoxyarylsilanes and N-benzoyloxyamines. Silver fluoride serves as a stoichiometric base as well as an indispensable activator that allows the catalytic process to proceed. Multiply alkoxylated arylsilanes, such as trialkoxyarylsilanes and dialkoxyarylsilanes were transformed into the corresponding tertiary anilines under mild reaction conditions.

TRICYCLIC COMPOUND SERVING AS IMMUNOMODULATOR

Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer.

1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS

The present invention provides compounds of formula (1) compositions comprising such compounds; the use of such compounds in therapy (such as in the treatment of dysmenorrhoea); and methods of treating patients with such compounds; wherein A and G are as defined herein.

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras